Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

44.49
-0.3600-0.80%
Post-market: 44.490.00000.00%17:35 EDT
Volume:634.14K
Turnover:28.12M
Market Cap:2.73B
PE:10.52
High:44.84
Open:44.36
Low:43.62
Close:44.85
Loading ...

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
19 Feb

Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals?

Simply Wall St.
·
14 Feb

Protagonist Therapeutics participates in a conference call with Truist

TIPRANKS
·
08 Feb

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

Protagonist Therapeutics (PTGX) Receives a Buy from Truist Financial

TIPRANKS
·
07 Feb

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
07 Feb

Promising Potential of Rusfertide in Treating Polycythemia Vera Drives Buy Rating for Protagonist Therapeutics

TIPRANKS
·
07 Feb

Positive Outlook on Protagonist Therapeutics: Potential of Rusfertide in Addressing Polycythemia Vera Needs

TIPRANKS
·
07 Feb

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
07 Feb

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
04 Feb

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

ACCESS Newswire
·
30 Jan

Protagonist Therapeutics Reports Granting of Inducement Awards

ACCESSWIRE
·
07 Jan

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

ACCESSWIRE
·
20 Dec 2024

Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership

TIPRANKS
·
11 Dec 2024

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

Protagonist Therapeutics: Promising Developments and Positive Outlook Justify Buy Rating

TIPRANKS
·
10 Dec 2024

Protagonist Therapeutics announces data from REVIVE study at ASH

TIPRANKS
·
10 Dec 2024

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

ACCESSWIRE
·
10 Dec 2024

Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target

MT Newswires Live
·
06 Dec 2024

Protagonist Therapeutics Inc : Bmo Initiates Coverage With Outperform Rating; Price Target $62

THOMSON REUTERS
·
06 Dec 2024